This site is intended for healthcare professionals

Travere Therapeutics announces achievement of interim proteinuria endpoint in the phase III DUPLEX study of sparsentan for focal segmental glomerulosclerosis.

Read time: 1 mins
Last updated:28th Jun 2021
Published:3rd Feb 2021
Condition: Focal Segmental Glomerulosclerosis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest